Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.
暂无分享,去创建一个
V. Seshan | A. Zelenetz | D. Mould | M. Fleisher | S. Horwitz | F. Sirotnak | O. O’Connor | P. Hamlin | C. Moskowitz | C. Portlock | B. Macgregor-Cortelli | E. Neylon | D. Sarasohn | M. Saunders | Molly Patterson | Jill Mastrella | Rachel Hamelers | Barbara Macgregor-Cortelli | M. Patterson